Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
The influence of norethisterone acetate on urinary urodilatin excretion in postrnenopausal women
We have previously found that transdermal estradiol application significantly stimulated the urinary excretion of urodilatin, a newly discovered renal peptide with diuretic properties. It is well established that the addition of progestogen is necessary in hormone replacement therapy in women with an intact uterus. This study was designed specifically to examine the effect of progestogen norethisterone acetate (NETA) in postmenopausal women. NETA given alone orally in dosages of 1 mg/d and 2 mg/d for 10 days, as use for the progestogen-challenge test, did not increase urodilatin excretion. NETA in combination with estradiol, administered orally and transdermally in the second half of a 4-week estradiol treatment cycle, did not significantly change urodilatin excretion. The results of the present study indicate that NETA addition to esttrogen replacement therapy may antagonize the stimulating estradiol effect on urodilatin production as registered in our earlier study.